We figured that there was no aclacinomycin in the chemotherapeutic regimen of homoharringtonine, cytarabine and dasatinib at the first time when the patient developed acute pancreatitis, and there was no homoharringtonine in the regimen of the aclacinomycin, cytarabine, G-CSF and dasatinib at the second time, considering that the possibility of the acute pancreatitis induced by these two drugs was relatively low. The gene discussed is CSF3; the disease is acute pancreatitis.